Project Grant HT9425261E382
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $140K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The Defense Health Agency awarded The Washington University $140,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to identify small molecules targeting the P14ARF pathway to treat CDKN2A-deficient malignant peripheral nerve sheath tumor. Work is performed in University City, Missouri, with a period of performance through August 31, 2028. The award is structured as a Project Grant, a common assistance type within the Defense Health Program's...
- The Defense Health Agency awarded The Washington University $769,999 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research on control of dendritic cell dysfunction induced by gamma-delta regulatory T cells for melanoma immunotherapy. The award funds a three-year project period running through July 31, 2029, with performance in University City, Missouri. The recipient organization is the Office of Sponsored Research Services Division of...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- The Defense Health Agency awarded University of Massachusetts Medical School $1.699 million on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to determine the contribution of interferon gamma signaling to neuroendocrine prostate cancer progression and immunotherapy resistance. The three-year project runs through June 30, 2029, with work performed in Worcester, Massachusetts. The award supports basic biomedical research to investigate medical solutions...
- The Defense Health Agency (DHA) awarded the University of Washington a $543,285 Project Grant under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2025, with a completion date of July 31, 2028. This award supports research focused on transforming rhabdomyosarcoma treatment through the development and evaluation of new FDA-approved combination therapies. The project will be conducted at the University of Washington's Seattle, Washington location under the...
- The Defense Health Agency awarded the University of Pittsburgh $1,462,665 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate the intratumoral microbiome in acral melanoma. The three-year project runs through June 30, 2029, and is performed in Pittsburgh, Pennsylvania. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American...
- The Defense Health Agency awarded The Washington University $840,000 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate hyperphosphorylation of tau serine 262 as a novel biomarker and therapy target in amyotrophic lateral sclerosis (ALS). Work is performed in University City, Missouri, with a period of performance through May 31, 2028. The award supports basic and applied biomedical research to transform health care for Service Members and...
- The Defense Health Agency awarded The Trustees of Columbia University in the City of New York $956,000 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on inducing lipid peroxidation in melanoma cells in lymph nodes to promote systemic immunosurveillance. Work is performed in New York, New York, with a period of performance from September 1, 2026, through August 31, 2029. The Military Medical Research and Development program...
- The Defense Health Agency awarded New York University School of Medicine $750,962 on June 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate neoadjuvant checkpoint and IL-6 blockade mechanisms of benefit and toxicity. The award supports basic and applied biomedical research with a period of performance through June 14, 2029. Work is performed in New York, New York. The Military Medical Research and Development program funds research to transform...
- The Defense Health Agency awarded The Wistar Institute of Anatomy and Biology $560,000 on August 15, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research dissecting acral melanoma cell state-specific vulnerabilities for targeted intervention. Work is performed in Philadelphia, Pennsylvania, with a period of performance through August 14, 2028. The award funds basic and translational biomedical research in melanoma immunotherapy, aligning with the...